Table 3.

Relative time to the composite end point according to indices of mineral metabolism

Characteristic	Model 1			Model 2			Model 3			Model 4
	Minimally Adjusteda			+Adjusted for GFR, Up/cb			Multivariable Adjustedc			+Mineral Metabolitesd
	RT	95% CI	P Value	RT	95% CI	P Value	RT	95% CI	P Value	RT	95% CI	P Value
Plasma FGF23 tertiles, RU/ml
<100		Reference			Reference			Reference			Reference
100–169	0.56	0.39 to 0.79	0.001	0.70	0.51 to 0.95	0.02	0.68	0.51 to 0.92	0.01	0.69	0.50 to 0.94	0.02
≥170	0.31	0.22 to 0.44	<0.001	0.59	0.43 to 0.80	0.001	0.60	0.44 to 0.81	0.001	0.59	0.42 to 0.82	0.002
P for linear trend			<0.001			0.003			0.004			0.0
Plasma FGF23, per doubling	0.64	0.56 to 0.72	<0.001	0.81	0.73 to 0.91	<0.001	0.82	0.74 to 0.91	<0.001	0.82	0.73 to 0.92	0.001
Serum 1,25(OH)2D tertile, pg/ml
>34		Reference			Reference			Reference			Reference
25–34	0.66	0.45 to 0.96	0.03	0.81	0.59 to 1.1	0.18	0.84	0.61 to 1.14	0.26	0.88	0.65 to 1.19	0.41
<25	0.42	0.29 to 0.61	<0.001	0.71	0.52 to 0.97	0.03	0.80	0.58 to 1.09	0.15	0.83	0.61 to 1.13	0.24
P for linear trend			<0.001			0.09			0.34			0.50
Serum 1,25(OH)2D, per 10 pg/ml lower	0.66	0.57 to 0.76	<0.001	0.84	0.74 to 0.95	0.0	0.89	0.79 to 0.99	0.03	0.90	0.80 to 1.00	0.06

⁺, additionally adjusted; Up/c, urine protein-to-creatinine ratio; RT, relative time; 95% CI, 95% confidence interval; FGF23, fibroblast growth factor 23; 1,25(OH)₂D, 1,25-dihydroxyvitamin D.

^aAdjusted for gender, age, and race.

^bAdditionally adjusted for GFR, Up/c.

^cAdditionally adjusted for systolic BP z-score, glomerular diagnosis, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers, active vitamin D, and phosphate binder use. This is the primary model of interest.

^dAdditionally adjusted for mineral metabolites [phosphorus z-score, tertiles of FGF23, 25OHD, and 1,25(OH)₂D] other than the primary exposure variable.